PCIA
ALXN

Prime Capital Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Prime Capital Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-452
Closed -$69K – 575
2021
Q1 		$69K Sell
452
-348
-44% -$53.8K 0.01% 311
2020
Q4 		$125K Sell
800
-150
-16% -$19.3K 0.01% 263
2020
Q3 		$109K Hold
950
– – 0.01% 274
2020
Q2 		$107K Sell
950
-9
-0.9% -$956 0.01% 273
2020
Q1 		$86K Buy
959
+252
+36% +$24.7K 0.01% 255
2019
Q4 		$76K Sell
707
-400
-36% -$42.8K 0.01% 270
2019
Q3 		$108K Buy
1,107
+557
+101% +$62.8K 0.02% 241
2019
Q2 		$72K Hold
550
– – 0.01% 222
2019
Q1 		$74K Buy
+550
New +$68.4K 0.02% 173

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Prime Capital Investment Advisors's ALXN Position: Q2 2021 in Review

Prime Capital Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 452 shares — an estimated $69K sold.

Prime Capital Investment Advisors first reported a position in ALXN in Q1 2019 and held it in 9 quarters. The position peaked at $125K in Q4 2020. 708 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

  • Prime Capital Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 452 Alexion Pharmaceuticals shares in Q2 2021, an estimated $69K.
  • Prime Capital Investment Advisors first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 9 quarters.
  • Prime Capital Investment Advisors's Alexion Pharmaceuticals position peaked at $125K in Q4 2020.
  • 708 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Prime Capital Investment Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.